MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA, INC., and AKORN INC., Petitioners v. ALLERGAN, INC., Patent Owner
In an amicus brief submitted to the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trade Office, AAM urged the PTAB to reject Allergan’s effort to avoid the PTAB review of the validity of its patents by renting the sovereign immunity of the St. Regis Mohawk Tribe. Brand name drug companies who […]
HELSINN v. TEVA
In an amicus brief submitted to the Supreme Court, AAM called on the court to reject one form of patent system manipulation attempted by a brand-name drug company. AAM’s brief emphasizes the extent to which Helsinn’s interpretation of the on-sale bar would invite manipulation and foster confusion in the pharmaceutical market, with deleterious consequences for patients, […]
OIL STATES ENERGY SERVICES, LLC, PETITIONER v. GREENE’S ENERGY GROUP, LLC, ET AL.
In an amicus brief submitted to the Supreme Court, AAM urged the Court to uphold the constitutionality of the Inter Partes Review (IPR) process established at the U.S. Patent and Trade Office under the America Invents Act of 2011. AAM explained the important role that the IPR process plays in weeding out invalid patents in […]
Expanding Patient Access by Preserving Drug Patent Challenges
One of the more complex ways that brand drug companies can hinder competition is by taking advantage of the patent process. Instances of brand company “evergreening,” making minor changes to a product and pursuing a new patent with its requisite protection from competition are commonplace. When this results in more revenue for the protected brand […]
AAM Response to CA Governor Newsom Signing AB 824
WASHINGTON, DC (October 8, 2019)– “As the Federal Trade Commission has found, recent patent litigation settlements have overwhelmingly accelerated the launch of more affordable generic and biosimilar medicines prior to the branded drug’s patent expiration date. Increased competition from generics and biosimilars break up drug monopolies and drive down the cost of medicine. California patients […]
National Survey Finds Significant Voter Opposition to Patent Settlement Legislation
Voters believe measure will result in higher drug prices WASHINGTON, DC (July 2, 2019) — A recent national survey finds by a margin of 4-1 that registered voters believe that patent settlement legislation will result in higher drug prices. The generic industry opposes proposed legislation, as it would make it significantly more difficult to challenge patents […]
Section 205 is Still Flawed and Erodes the Only Incentive to Challenge Brand-Name Drug Patents. Here’s Why.
In the manager’s amendment to the Lower Health Care Costs Act released yesterday, several changes were included to Section 205 (preventing blocking of generics). For the 180-day clock to be triggered under Section 205 as originally proposed, four conditions needed to occur: 1) a subsequent applicant has received tentative approval that could be made final […]
AAM Statement on FTC Report on Patent Settlements
WASHINGTON, DC (May 23, 2019) — By FTC’s own account, current law is working and reverse payment settlements are no longer a systemic problem. Current “pay-for-delay” legislation, however, would unfortunately overturn the Actavis decision and unwind the many pro-competitive benefits that lower prescription drug costs for patients. We urge policymakers to revisit the need for legislation […]
AAM Statement on Introduction of the Affordable Prescriptions for Patients Act
WASHINGTON, DC (May 8, 2019) — AAM commends Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT) for seeking to address two significant obstacles to generic drug and biosimilar competition: product-hopping and the creation of patent thickets. Brand-name drug companies are able to employ these strategies to prevent automatic substitution of generics and extend brand-name drug […]
AAM Statement: Senate Judiciary Committee Hearing on Patents and Drug Prices
Association for Accessible Medicines Statement on Senate Judiciary Committee Hearing, “Intellectual Property and the Price of Prescription Drugs: Balancing Innovation and Competition.” WASHINGTON, DC (May 7, 2019) — AAM has worked extensively with the Senate Judiciary Committee to ensure that the patent system strikes an appropriate balance. We are especially grateful for this Committee’s work […]
Patent Settlements DO Help Patients
Check the Facts on “Pay-for-Delay” Legislation! Download our full fact sheet on patent settlements: Fact Sheet Settlements Get Affordable Rx to Patients Faster. Misguided Legislation Hurts Access. Additional Resources: Read NTU Oped: More Power to Federal Trade Commission over Medicines: What Could Possibly Go Wrong? Download NTU Issue Brief Read Issue Brief Patent Settlements that Resulted […]
AAM Welcomes Re-Introduction of the PACED Act
WASHINGTON, DC (February 13, 2019) — With everyone from patients to the President demanding action on drug pricing, AAM welcomes the re-introduction of the Preserving Access to Cost Effective Drugs (PACED) Act. As pharmaceutical companies continue to find novel ways to game the system to keep their monopolies intact long past their expiration date, the […]
